{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=6", "query": { "condition": "Metastatic Skin Cancer", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 2838, "total_pages": 284, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T10:17:11.620Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00834678", "title": "Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "bendamustine", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" }, { "name": "Maintenance erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2009-04", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2018-04-17", "last_synced_at": "2026-11-15T10:17:11.620Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00834678" }, { "nct_id": "NCT00034125", "title": "Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "LY353381", "type": "DRUG" }, { "name": "tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2006-07-19", "last_synced_at": "2026-11-15T10:17:11.620Z", "location_count": 4, "location_summary": "Miami, Florida • Shreveport, Louisiana • Boston, Massachusetts + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00034125" }, { "nct_id": "NCT03454243", "title": "Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "RXDX-106", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-02-15", "completion_date": "2018-06-05", "has_results": false, "last_update_posted_date": "2019-04-25", "last_synced_at": "2026-11-15T10:17:11.620Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03454243" }, { "nct_id": "NCT01655225", "title": "A Study of LY3023414 in Participants With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Non-Hodgkin's Lymphoma", "Metastatic Breast Cancer", "Malignant Mesothelioma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "LY3023414", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2012-07-31", "completion_date": "2022-02-02", "has_results": false, "last_update_posted_date": "2022-04-08", "last_synced_at": "2026-11-15T10:17:11.620Z", "location_count": 6, "location_summary": "Los Angeles, California • New York, New York • Oklahoma City, Oklahoma + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01655225" }, { "nct_id": "NCT06805825", "title": "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Stromal Tumors", "Small-cell Lung Cancer", "Adenoid Cystic Carcinoma", "Uveal Melanoma", "Neuroendocrine Tumors", "Chromophobe Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "NN3201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novelty Nobility, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2025-02-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-11-13", "last_synced_at": "2026-11-15T10:17:11.620Z", "location_count": 5, "location_summary": "Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06805825" }, { "nct_id": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Metastatic Breast Cancer", "Advanced Breast Cancer", "HER2 Mutation-Related Tumors", "HER2-positive Metastatic Breast Cancer", "KRAS Mutant Metastatic Colorectal Cancer", "Metastatic Lung Cancer", "Metastatic Colorectal Cancer", "Advanced Lung Cancer", "HR-positive, HER2-negative Advanced Breast Cancer", "HER2-positive Advanced Breast Cancer" ], "interventions": [ { "name": "BBO-10203", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 392, "start_date": "2024-10-29", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-11-15T10:17:11.620Z", "location_count": 19, "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625775" }, { "nct_id": "NCT05864144", "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Advanced Solid Tumor", "Head and Neck Cancer", "Breast Cancer", "Colon Cancer", "Pancreatic Cancer", "Gastric Cancer", "Esophageal Cancer", "Prostate Cancer", "Uterine Cancer", "Cervix Cancer", "Ovarian Cancer", "Kidney Cancer", "Bladder Cancer", "Thyroid Cancer", "Melanoma", "Sarcoma", "Advanced Cancer", "Metastatic Cancer", "Refractory Cancer", "Non Small Cell Lung Cancer", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "SNS-101 (anti-VISTA)", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sensei Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2023-05-31", "completion_date": "2026-06-02", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-11-15T10:17:11.620Z", "location_count": 10, "location_summary": "Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05864144" }, { "nct_id": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Fallopian Tube Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Ovarian Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Primary Peritoneal Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Melanoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2015-06-26", "completion_date": "2024-09-16", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-11-15T10:17:11.620Z", "location_count": 5, "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more", "locations": [ { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419495" }, { "nct_id": "NCT04039230", "title": "Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Talazoparib", "type": "DRUG" }, { "name": "Sacituzumab Govitecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 75, "start_date": "2019-10-09", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-11-15T10:17:11.620Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04039230" }, { "nct_id": "NCT07085767", "title": "Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Locally Advanced Breast Cancer", "Metastatic Breast Cancer", "ER Positive Breast Cancer", "HER2 Negative Breast Carcinoma" ], "interventions": [ { "name": "Palazestrant", "type": "DRUG" }, { "name": "Letrozole-matching placebo", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Palazestrant matching-placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Olema Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2025-11-03", "completion_date": "2032-01", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-11-15T10:17:11.620Z", "location_count": 62, "location_summary": "Hot Springs, Arkansas • Beverly Hills, California • La Jolla, California + 54 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07085767" } ] }